Mind Cure Health (CSE: MCUR) has a new executive. The company this morning announced that appointment of Dr Ryan Hartwell as the firms Chief Science Officer. After months of serving on the firms scientific advisory board, Hartwell has taken the jump to lead the scientific team at the company.
A successful entrepeneur, scientist, inventor, and researcher, Hartwell appears to be highly qualified for the role. He previously founded ATS Biotech, a biomedical wound care company, while also acting as co-inventory of both FS2 and AI-001 cell therapy. Further, he also received the Vancouver Coastal Health Research Institute Award for top graduating doctoral student following the completion of his Ph.D. in experimental medicine at UBC.
Hartwell is to focus on the advancement of Mind Cure’s research and product development, and will be tasked with the role of leading efforts to research both psychoactive and psychedelic substances and their therapeutic benefits for the company. His role is to have a direct impact on establishing Mind Cure as a leader within the mental health space.
Commenting on the appointment, Hartwell stated, “From all that we have learned in studying psychedelics, the opportunity to chart a new path toward a better understanding and discovery of effective medicines provides tremendous potential to transform mental health and aging wellness.”
Sponsored · Altamira Gold Corp.
Mind Cure Health last traded at $0.64 on the CSE.
FULL DISCLOSURE: Mind Cure Health is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Mind Cure Health on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
